Skip to main content
Prelude Therapeutics Inc logo

Prelude Therapeutics Inc — Investor Relations & Filings

Ticker · PRLD ISIN · US74065P1012 US Manufacturing
Open in API
Filings indexed 356 across all filing types
Latest filing 2021-11-19 Director's Dealing
Country US United States of America
Listing US PRLD

About Prelude Therapeutics Inc

https://preludetx.com/

Prelude Therapeutics is a clinical-stage precision oncology company focused on discovering and developing innovative medicines for cancer patients with high unmet needs. The company's pipeline features small molecule therapies and leverages expertise in targeted protein degradation. Key development programs include highly selective KAT6A degraders for solid tumors, such as ER+ breast cancer, and mutant-selective JAK2V617F JH2 inhibitors for myeloproliferative neoplasms. Prelude is also advancing next-generation degrader antibody conjugates (DACs) with novel payloads. The company's science-driven approach targets critical cancer cell pathways to create potentially transformative treatments.

Recent filings

Filing Released Lang Actions
FORM 4 SUBMISSION
Director's Dealing
2021-11-19 English
S-3
Capital/Financing Update Classification · 95% confidence The document is a Form S-3 Registration Statement filed with the SEC under the Securities Act of 1933. It is a registration statement for securities offerings, including common stock, preferred stock, debt securities, warrants, subscription rights, and units. The document includes details about the registration fee, offering amounts, and the selling stockholders. It is not a financial report, earnings release, or management discussion, but rather a capital markets filing related to fundraising and securities issuance. Therefore, it fits the category of Capital/Financing Update (CAP). The document length is substantial (15,000 characters), and it contains detailed offering information, not just an announcement or a brief notice, so it is not an RPA or RNS. Confidence is high due to clear identification as a registration statement for securities offerings.
2021-11-12 English
10-Q
Interim / Quarterly Report Q3 2021
2021-11-12 English
8-K
Board/Management Information Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce major events that shareholders should know about. The content includes a financial results press release for the quarter ended September 30, 2021, but the actual financial results are in an attached press release (Exhibit 99.1), not fully contained in this document. It also announces a change in the Chief Financial Officer and details about his employment agreement, which is a management change. Additionally, it includes an investor presentation (Exhibit 99.2) but only as an attachment. The document itself is primarily an announcement of these events rather than the full financial report or presentation. The key event is the management change (CFO departure and appointment), which fits the Board/Management Information category. The financial results press release is referenced but not the full earnings release text, so it is not classified as ER. Therefore, the best classification is MANG (Board/Management Information). The document length (9657 characters) supports it being more than a brief announcement but still focused on management changes and related disclosures.
2021-11-12 English
FORM 4 SUBMISSION
Director's Dealing
2021-10-15 English
FORM 4 SUBMISSION
Director's Dealing
2021-10-07 English

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.